Genska terapija v onkologiji, prvi razvojni koraki v Sloveniji
Gene therapy in oncology, first steps of development in Slovenia

Authors

  • Maja Čemažar Institute of Oncology Ljubljana; Univerity of Primorska, Faculty of Health Sciences
  • Tanja Jesenko Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Maša Bošnjak Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Pharmacy
  • Boštjan Markelc Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Health Sciences
  • Urška Kamenšek Institute of Oncology Ljubljana; University of Ljubljana, Biotechnical Faculty
  • Simona Kranjc Brezar Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Špela Kos Institute of Oncology Ljubljana
  • Urša Lampreht Tratar Institute of Oncology Ljubljana
  • Katarina Žnidar Institute of Oncology Ljubljana
  • Andrej Renčelj Institute of Oncology Ljubljana
  • Urška Matkovič Institute of Oncology Ljubljana
  • Teja Valant Institute of Oncology Ljubljana
  • Kristina Levpušček Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Živa Modic Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Tilen Komel Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Tim Božič Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Urša Kešar Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Barbara Starešinič Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Katja Uršič Valentinuzzi Institute of Oncology Ljubljana; University of Ljubljana, Biotechnical Faculty
  • Monika Savarin Institute of Oncology Ljubljana; University of Primorska, Faculty of Health Sciences
  • Primož Strojan Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Medicine
  • Gorana Gašljević Institute of Oncology Ljubljana
  • Maja Ota Institute of Oncology Ljubljana
  • Aleš Grošelj University Medical Centre Ljubljana, Department of Otorhinolaryngology and Cervicofacial Surgery
  • Črt Jamšek University Medical Centre Ljubljana, Department of Otorhinolaryngology and Cervicofacial Surgery
  • Rosana Hudej Centre of Excellence for Biosensors, Instrumentation and Process Control (COBIK)
  • Matjaž Peterka Centre of Excellence for Biosensors, Instrumentation and Process Control (COBIK)
  • Frenk Smrekar JAFRAL d.o.o.
  • Barbara Hubad JAFRAL d.o.o.
  • Marjan Hosta Iskra PIO
  • Jaka Kužnik Iskra PIO
  • Lojze Hosta Iskra PIO
  • Damijan Miklavčič University of Ljubljana, Faculty of Electrical Engineering
  • Matej Reberšek University of Ljubljana, Faculty of Electrical Engineering
  • Aleksandra Cvetkoska University of Ljubljana, Faculty of Electrical Engineering
  • Anja Zajc University of Ljubljana, Faculty of Electrical Engineering
  • Janja Dermol-Černe UUniversity of Ljubljana, Faculty of Electrical Engineering
  • Nataša Tozon University of Ljubljana, Veterinary Faculty, Small Animal Clinic
  • Nina Milevoj University of Ljubljana, Veterinary Faculty, Small Animal Clinic
  • Alenka Nemec Svete University of Ljubljana, Veterinary Faculty, Small Animal Clinic
  • Gregor Serša Institute of Oncology Ljubljana; University of Ljubljana, Faculty of Health Sciences

DOI:

https://doi.org/10.25670/oi2022-002on

Keywords:

Gene therapy, interleukin 12, plasmid DNA, gene electrotransfer, clinical study Phase I, head and neck skin tumors

Abstract

Genska terapija postaja čedalje bolj zanimiva tudi v onkologiji. Med aplikacijami je morda najzanimivejša imunostimulacija. Pripravimo lahko plazmidno DNA, ki nosi zapis za različne imunostimulatorne molekule, ki jih vnesemo v celice tumorjev ali normalnih tkiv. Ta tkiva postanejo proizvajalci teh molekul, ki lahko delujejo lokalno ali pa se izločajo tudi sistemsko v krvni obtok. Ker plazmidna DNA ne prehaja celične membrane, so potrebni dostavni sistemi, virusni ali nevirusni. V naših študijah uporabljamo predvsem nevirusni dostavni sistem – elektroporacijo.
Interlevkin 12 (IL-12) je eden od zanimivih citokinov, za katerega je znano protitumorsko delovanje s spodbujanjem imunskega odziva in antiangiogenim delovanjem. Namen projekta SmartGene.si je bil pripraviti plazmid z zapisom za interlevkin 12 (plazmid phIL12) in pripraviti vse potrebno za njegovo klinično testiranje za zdravljenje kožnih tumorjev. V konzorciju smo združili moči s partnerji z akademskega in industrijskega področja. Treba je bilo pripraviti plazmid za uporabo v humani onkologiji po zahtevah Evropske agencije za zdravila (EMA). Za prijavo klinične študije na Javno agencijo za zdravila in medicinske pripomočke (JAZMP) smo morali izvesti tudi vse neklinične raziskave o varnosti in učinkovitosti zdravila. Nato je bilo treba razviti postopek priprave zdravila, zagotoviti primerne prostore za pripravo in izvedbo postopka priprave zdravila.
V treh letih smo dosegli vse te zastavljene cilje in dobili dovoljenje za izvajanje klinične študije na kožnih tumorjih, ki ga je izdala JAZMP na osnovi pozitivnega mnenja Komisije Republike Slovenije za medicinsko etiko. Zdaj poteka klinična študija faze I preizkušanja plazmida phIL12 na kožnih tumorjih glave in vratu z namenom preveriti varnost in sprejemljivost genskega elektroprenosa plazmida v tumorje. Cilj študije je prav tako določiti primeren odmerek zdravila, ki bi ga v nadaljnji klinični študiji uporabili kot adjuvantno zdravljenje k ablativnim terapijam, kot sta radioterapija ali elektrokemoterapija.


Abstract (Eng)

Gene therapy is also attracting interest in oncology. Probably the most interesting approach is immunostimulation. Plasmid DNA can be constructed, which is coding for a specific immunostimulatory molecule, which is then delivered into the cells, either in tumour or normal tissue. The transfected tissue then becomes the producer of the molecules encoded in the plasmid. The product is then released from the cells, either locally or systemically into the bloodstream. Since plasmids have hampered transport through the plasma membrane, delivery systems are needed that are either viral or nonviral. In our studies we predominantly use the non-viral transfection system, based on electroporation of the cells.
Interleukin 12 (IL-12) is a cytokine with well-known anti-tumour and anti-angiogenic function. Therefore, in the SmartGene.si project we wanted to construct a plasmid DNA which is coding for IL-12 (plasmid phIL12), and perform all the necessary testing and prepare the documentation for its clinical testing in the treatment of skin tumours. The SmartGene.si consortium comprises partners from academia and industry. In the project it was necessary to prepare the plasmid according to the European Medicinal Agency (EMA) recommendations. For the application for the study approval submitted to the Agency for Medical Products and Medical Devices of the Republic of Slovenia (JAZMP), it was necessary to perform pharmacological, pharmacokinetic, and efficiency testing of phIL12. Thereafter, we had to develop the process and the facility, and prepare the drug.
During the last three years, we have achieved all the goals and obtained the approval of the JAZMP for clinical testing of the product phIL12 in humans. We also obtained the approval of the National Ethics Committee. Currently, we are testing phIL-12 in a Phase I clinical protocol on head and neck skin tumours, with the aim to test the safety and feasibility of intratumoral gene electrotransfer of the plasmid phIL12. Another goal of the study is to determine a suitable dose of plasmid that could be used in future studies as adjuvant treatment to ablative therapies such as radiotherapy or electrochemotherapy.

Downloads

Published

2022-05-11

How to Cite

Čemažar, M., Jesenko, T., Bošnjak, M., Markelc, B., Kamenšek, U., Kranjc Brezar, S., Kos, Špela, Lampreht Tratar, U., Žnidar, K., Renčelj, A., Matkovič, U., Valant, T., Levpušček, K., Modic, Živa, Komel, T., Božič, T., Kešar, U., Starešinič, B., Uršič Valentinuzzi, K., Savarin, M., Strojan, P., Gašljević, G., Ota, M., Grošelj, A., Jamšek, Črt, Hudej, R., Peterka, M., Smrekar, F., Hubad, B., Hosta, M., Kužnik, J., Hosta, L., Miklavčič, D., Reberšek, M., Cvetkoska, A., Zajc, A., Dermol-Černe, J., Tozon, N., Milevoj, N., Nemec Svete, A., & Serša, G. (2022). Gene therapy in oncology, first steps of development in Slovenia. Onkologija : Slovenian Journal of Oncology, 26(1), 12–21. https://doi.org/10.25670/oi2022-002on

Issue

Vol. 26 No. 1 (2022)

Section

Review Article

License

Copyright (c) 2022 Maja Čemažar, Tanja Jesenko, Maša Bošnjak, Boštjan Markelc, Urška Kamenšek, Simona Kranjc Brezar, Špela Kos, Urša Lampreht Tratar, Katarina Žnidar, Andrej Renčelj, Urška Matkovič, Teja Valant, Kristina Levpušček, Živa Modic, Tilen Komel, Tim Božič, Urša Kešar, Barbara Starešinič, Katja Uršič Valentinuzzi, Monika Savarin, Primož Strojan, Gorana Gašljević, Maja Ota, Aleš Grošelj, Črt Jamšek, Rosana Hudej, Matjaž Peterka, Frenk Smrekar, Barbara Hubad, Marjan Hosta, Jaka Kužnik, Lojze Hosta, Damijan Miklavčič, Matej Reberšek, Aleksandra Cvetkoska, Anja Zajc, Janja Dermol-Černe, Nataša Tozon, Nina Milevoj, Alenka Nemec Svete, Gregor Serša

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.

This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.

Funding data